CHOLESTEROL PARADOX IN PATIENTS WITH CHRONIC CARDIAC INSUFFICIENCY MODERN STATE OF THE PROBLEM
https://doi.org/10.21518/2079-701X-2016-13-61-65
Abstract
Chronic cardiac insufficiency (CCI) is a wide-spread disease among the population of the Russian Federation and, as a rule, it is related to presence of the ischemic heart disease (IHD). Hypercholesterinemia is the major risk factor of IHD development but, however paradoxical it might seem, IHD patients often present a low cholesterol level, which, in its turn, is associated with the bad forecast. Reduction of the cholesterol level by statins reduces the incidence and mortality rate in IHD patients without CCI and possible improves the forecast in patients with CCI. But results of a number of studies testify that the high cholesterol level in patients with CCI is associated with better survival rates. This article provides data on the cholesterol paradox in CCI patients, its possible mechanisms and modern algorithms of the above-stated patients group management.
About the Author
R. N. SHEPEL
State Scientific and Research Center of Preventive Medicine of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Pekkanen J, Linn S, Heiss G et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med, 1990, 322: 1700-1707.
2. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J, 1991, 121: 951-957.
3. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail, 1997, 3: 249-254.
4. Vredevoe DL, Woo MA, Doering LV et al. Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol, 1998, 82(3): 323-328.
5. Richartz BM, Radovancevic B, Frazier OH et al. Low serum cholesterol levels predict high perioperative mortality in patients supported by a left-ventricular assist system. Cardiology, 1998, 89(3): 184-188.
6. Rauchhaus M, Koloczek V, Volk H et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol, 2000, 76(2–3): 125-33.
7. Rauchhaus M, Clark AL, Doehner W et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol, 2003, 2(11): 1933-1940.
8. Afsarmanesh N, Horwich TB, Fonarow GC. Total cholesterol levels and mortality risk in nonischemic systolic heart failure. Am Heart J, 2006, 152(6): 1077-1083.
9. May HT, Muhlestein JB, Carlquist JF et al. Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. Am J Cardiol, 2006, 98: 653- 658.
10. Greene SJ, Vaduganathan M, Lupi L et al. Prog nostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol, 2013, 111(4): 574-81.
11. Freitas HF, Barbosa EA, Rosa FH et al. Association of HDL cholesterol and triglycerides with mortality in patients with heart failure. Braz J Med Biol Res, 2009, 42(5): 420-405.
12. Horwich TB, Hernandez AZ et al. Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. Am Heart J, 2008, 156(6): 1170-1076.
13. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis, 2011, 70: 482-487.
14. Yoon CH, Youn TJ, Ahn S et al. Korean Heart Failure Registry. Low serum total cholesterol level is a surrogate marker, but not a risk factor, for poor outcome in patients hospitalized with acute heart failure: a report from the Korean Heart Failure Registry. J Card Fail, 2012, 18(3): 194-201.
15. Volpato S, Leveille SG, Corti MC et al. The value of serum albumin and high-density lipoprotein cholesterol in defining mortality risk in older persons with low serum cholesterol. J Am Geriatr Soc, 2001, 49: 1142-1147.
16. Volpato S, Zuliani G, Guralnik JM et al. The inverse association between age and cholesterol level among older patients: The role of poor health status. Gerontology, 2001, 47: 36-45.
17. Krumholz HM, Seeman TE, Merrill SS et al. Lack of association between cholesterol and coronary heart diseaёse mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA, 1994, 272: 1335-1340.
18. Bonilla-Palomas JL, Gámez-López AL, Moreno- Conde M et al. Total cholesterol levels predict inhospital mortality in patients with acute heart failure aged 70 years or older. Rev Esp Geriatr Gerontol, 2016, 13. pii: S0211-139X(15)00238-3.
19. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther, 2003, 99(1): 95-112.
20. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344 (8934): 1383-1389.
21. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995, 333(20): 1301-1307.
22. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 1998, 339(19): 1349-1357.
23. Anker SD, Chua TP, Swan JW. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure. The importance for cardiac cachexia. Circulation, 1997, 96: 526-534.
24. Pasini E, Aquilani R, Gheorghiade M et al. Malnutrition, muscle wasting and cachexia in chronic heart failure: The nutritional approach. Ital Heart J, 2003, 4: 232-235.
25. Anker SD, Ponikowski P, Varney S et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet, 1997, 349: 1050-1053.
26. Witte KK, Clark AL. Nutritional abnormalities contributing to cachexia in chronic illness. Int J Cardiol, 2002, 85: 23-31.
27. Anker SD, Coats AJ. Cardiac cachexia: A syndrome with impaired survival and immune and neuroendocrine activation. Chest, 1999, 115: 836-847.
28. Anker SD, Chua TP, Ponikowski P et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation, 1997, 96: 526-534.
29. Rauchhaus M, Clark AL, Doehner W et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol, 2003, 42: 1933-1940.
30. Mortensen SA, Leth A, Agner E, Rohde M. Doserelated decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med, 1997, 18(Suppl): S137-S144.
31. Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet, 2004, 363(9412): 892-894.
32. Драпкина О.М., Шепель Р.Н. Статины и риск развития инфекционных заболеваний. Рациональная фармакотерапия в кардиологии, 2013, 9(3): 306-310./ Drapkina O.M., Shepel R.N. Statins and risk of infectious diseases development. Ratsionalnaya farmakoterapia v kardiologii, 2013, 9 (3): 306-310.
33. Kjekshus J, Dunselman P, Blideskog M et al. A statin in the treatment of heart failure, Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail, 2005, 7: 1059-69.
34. GISSIР-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSIРHF trial): a randomized, doubleР blind, placeboРcontrolled trial. Lancet, 2008, 372: 1231-1239.
35. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная Недостаточность, 2013, 81(7): 379-472./ National Recommendations of Cardiovascular Insufficiency Expert Association, Russian Cardiologic Society and Russian Scientific Medical Therapist Society on diagnostics and therapy of CCI (Revision Four). Serdechnaya Nedostatochnost Journal, 2013, 81 (7): 379- 472.
Review
For citations:
SHEPEL RN. CHOLESTEROL PARADOX IN PATIENTS WITH CHRONIC CARDIAC INSUFFICIENCY MODERN STATE OF THE PROBLEM. Meditsinskiy sovet = Medical Council. 2016;(13):61-65. (In Russ.) https://doi.org/10.21518/2079-701X-2016-13-61-65
Views:
965
Email this article 